RecruitingPhase 1NCT06047977

Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors

Tumor Infiltrating Lymphocytes in Pediatric Malignant Solid Tumors: A Prospective Biobanking Study and Phase I Clinical Trial

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Enrollment

30 participants

Start Date

Jun 2, 2025

Study Type

INTERVENTIONAL

Conditions

Lymphocytes

Summary

Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors. Part Two of this study will determine the safety of TIL therapy with lymphodepleting chemotherapy and post-TIL Interleukin-2 in high-risk pediatric solid tumors

Eligibility

Min Age: 1 YearMax Age: 21 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2 for people with lymphocytes. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALTumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2

Lymphodepleting Chemotherapy with Fludarabine/Cyclophosphamide followed by TIL and Post-TIL Interleukin-2 (IL-2)

Locations(1)

Johns Hopkins All Children's Hospital

St. Petersburg, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06047977